Φορτώνει......

Higher stem cell dose infusion after intensive chemotherapy does not improve symptom burden in older patients with multiple myeloma and amyloidosis

Autologous hematopoietic stem cell transplantation (ASCT) for multiple myeloma (MM) is associated with high symptom burden, particularly for older patients and those with amyloid light-chain (AL) amyloidosis. Symptom burden peaks during leukopenia. We hypothesized that higher doses of CD34(+) stem c...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:	Biol Blood Marrow Transplant
Κύριοι συγγραφείς:	Shah, Nina, Shi, Qiuling, Williams, Loretta A., Mendoza, Tito R., Wang, Xin Shelley, Reuben, James M., Dougherty, Patrick M., Bashir, Qaiser, Qazilbash, Muzaffar H., Champlin, Richard E., Cleeland, Charles S., Giralt, Sergio A.
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	2015
Θέματα:	Article
Διαθέσιμο Online:	https://ncbi.nlm.nih.gov/pmc/articles/PMC4716870/ https://ncbi.nlm.nih.gov/pubmed/26253006 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2015.07.036
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Higher stem cell dose infusion after intensive chemotherapy does not improve symptom burden in older patients with multiple myeloma and amyloidosis

Παρόμοια τεκμήρια